Exact Mass: 632.2958330000001
Exact Mass Matches: 632.2958330000001
Found 358 metabolites which its exact mass value is equals to given mass value 632.2958330000001
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
magnesium;3-[(3R,21S,22S)-11-ethyl-16-(1-hydroxyethyl)-3-methoxycarbonyl-12,17,21,26-tetramethyl-4-oxo-23,25-diaza-7,24-diazanidahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,5,8(26),9,11,13(25),14,16,18,20(23)-decaen-22-yl]propanoic acid
Bacteriochlorophyllide a
A chlorophyllide obtained by hydrolysis of the terpenoid ester moiety of bacteriochlorophyll a.
Coagulin R 3-glucoside
Coagulin R 3-glucoside is found in fruits. Coagulin R 3-glucoside is a constituent of Physalis peruviana (Cape gooseberry). Constituent of Physalis peruviana (Cape gooseberry). Coagulin R 3-glucoside is found in fruits.
Casokefamide
C33H40N6O7 (632.2958330000001)
PA(8:0/PGE2)
PA(8:0/PGE2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/PGE2), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of Prostaglandin E2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(PGE2/8:0)
PA(PGE2/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGE2/8:0), in particular, consists of one chain of one Prostaglandin E2 at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(8:0/PGD2)
PA(8:0/PGD2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/PGD2), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of Prostaglandin D2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(PGD2/8:0)
PA(PGD2/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGD2/8:0), in particular, consists of one chain of one Prostaglandin D2 at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(8:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))
PA(8:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of Lipoxin A4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/8:0)
PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/8:0), in particular, consists of one chain of one Lipoxin A4 at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
Ejap 5
Ejap 4
(5alpha,6alpha,7alpha,22R)-5-hydroxy-1,26-dioxo-6,7:22,26-diepoxyergosta-2,24-dien-27-yl beta-D-glucopyranoside|baimantuoluoside C
5,6,7,10-Tetraacetoxy-5a-(acetoxymethyl)-4-(benzoyloxy)-3,4,5,5a,6,7,8,9-octahydro-2,2,9-trimethyl-2H-3,9a-methano-1-benzooxepin
15-Acetoxy-2??,9??-di-(??-furancarbonyloxy)-4??,6??-dihydroxy-1??-(2-methylbutanoyloxy)-dihydro-??-agarofuran
20-O-benzoyl-12-O-cinnamoyl-3beta,5alpha,8beta,12beta,14beta,17beta,20-heptahydroxy-(20S)-pregn-6-ene
((aR,5R,6S,7R,8R)-5,6,7,8-tetrahydro-1,12-dihydroxy-2,3,10,11-tetramethoxy-6,7-dimethyl-5-[((E)-3-phenylprop-2-enoyl)oxy]dibenzo[a,c]cycloocten-5-yl) (Z)-2-methylbut-2-enoate|renchangianin C
6,7,10-Triacetoxy-5-(benzoyloxy)-3,4,5,5a,6,7,8,9-octahydro-5a-(2-methylbutanoyloxymethyl)-2,2,9-trimethyl-2H-3,9a-methano-1-benzooxepin-9-ol
6alpha-acetoxy-9beta-benzoyloxy-1beta-cinnamoyloxy-8beta-butanoyloxy-beta-dihydroagarofuran|6??-Acetoxy-9??-benzoyloxy-1??-cinnamoyloxy-8??-butanoyloxy-??-dihydroagarofuran
5,7,3,4-tetrahydroxy-6-(2-undecanonyl)-3-O-beta-D-galactopyranosyl flavonoid|houttuynoid E
5,7,3,4-tetrahydroxy-2-(2-undecanonyl)-3-O-beta-D-galactopyranosyl flavonoid|houttuynoid D
6alpha,8alpha,9beta,13-tetraacetoxy-1beta-cinnamoyloxy-2beta,4alpha-dihydroxy-beta-dihydroagarofuran
7alpha-acetoxy-2alpha,3alpha-dibenzoyloxy-1alpha,8beta-dihydroxyisopimar-15-ene-11,14-dione|orthoarisin C
20,27-dihydroxy-3beta-(O-beta-D-glucopyranosyl)-1-oxo-(20S,22R)-witha-5,14,24-trienolide|coagulin P
7,10-Diacetoxy-5a-(acetoxymethyl)-5-(benzoyloxy)-3,4,5,5a,6,7,8,9-octahydro-6-(2-methylbutanoyloxy)-2,2,9-trimethyl-2H-3,9a-methano-1-benzooxepin-9-ol
6,10-Diacetoxy-5a-(acetoxymethyl)-5-(benzoyloxy)-3,4,5,5a,6,7,8,9-octahydro-4-(2-methylbutanoyloxy)-2,2,9-trimethyl-2H-3,9a-methano-1-benzooxepin-9-ol
(2R,5S,6S,7R,8R,9R,10S,12S,18R,19S)-18,19-diacetoxy-18,19-epoxy-2,7-dihydroxy-6-[(2Z,4E)-decadienoyloxy]-12-hydroperoxycleroda-3,13(16),14-triene|argutin H
4,6,7,10-Tetraacetoxy-5a-(acetoxymethyl)-5-(benzoyloxy)-3,4,5,5a,6,7,8,9-octahydro-2,2,9-trimethyl-2H-3,9a-methano-1-benzooxepin
(2R,5S,6S,7R,8R,9R,10S,12S,18R,19S)-18,19-diacetoxy-18,19-epoxy-2-[(2Z,4E)-decadienoyloxy]-6,7-dihydroxy-12-hydroperoxycleroda-3,13(16),14-triene|argutin G
Tasumatrol F
A taxane diterpenoid isolated from Taxus sumatrana and has been shown to exhibit antineoplastic activity.
Glu Ile Trp Trp
C33H40N6O7 (632.2958330000001)
Glu Leu Trp Trp
C33H40N6O7 (632.2958330000001)
Glu Trp Ile Trp
C33H40N6O7 (632.2958330000001)
Glu Trp Leu Trp
C33H40N6O7 (632.2958330000001)
Glu Trp Trp Ile
C33H40N6O7 (632.2958330000001)
Glu Trp Trp Leu
C33H40N6O7 (632.2958330000001)
His Lys Trp Tyr
C32H40N8O6 (632.3070660000001)
His Lys Tyr Trp
C32H40N8O6 (632.3070660000001)
His Gln Trp Tyr
C31H36N8O7 (632.2706826000001)
His Gln Tyr Trp
C31H36N8O7 (632.2706826000001)
His Trp Lys Tyr
C32H40N8O6 (632.3070660000001)
His Trp Gln Tyr
C31H36N8O7 (632.2706826000001)
His Trp Tyr Lys
C32H40N8O6 (632.3070660000001)
His Trp Tyr Gln
C31H36N8O7 (632.2706826000001)
His Tyr Lys Trp
C32H40N8O6 (632.3070660000001)
His Tyr Gln Trp
C31H36N8O7 (632.2706826000001)
His Tyr Trp Lys
C32H40N8O6 (632.3070660000001)
His Tyr Trp Gln
C31H36N8O7 (632.2706826000001)
Ile Glu Trp Trp
C33H40N6O7 (632.2958330000001)
Ile Trp Glu Trp
C33H40N6O7 (632.2958330000001)
Ile Trp Trp Glu
C33H40N6O7 (632.2958330000001)
Lys His Trp Tyr
C32H40N8O6 (632.3070660000001)
Lys His Tyr Trp
C32H40N8O6 (632.3070660000001)
Lys Asn Trp Trp
C32H40N8O6 (632.3070660000001)
Lys Trp His Tyr
C32H40N8O6 (632.3070660000001)
Lys Trp Asn Trp
C32H40N8O6 (632.3070660000001)
Lys Trp Trp Asn
C32H40N8O6 (632.3070660000001)
Lys Trp Tyr His
C32H40N8O6 (632.3070660000001)
Lys Tyr His Trp
C32H40N8O6 (632.3070660000001)
Lys Tyr Trp His
C32H40N8O6 (632.3070660000001)
Leu Glu Trp Trp
C33H40N6O7 (632.2958330000001)
Leu Trp Glu Trp
C33H40N6O7 (632.2958330000001)
Leu Trp Trp Glu
C33H40N6O7 (632.2958330000001)
Asn Lys Trp Trp
C32H40N8O6 (632.3070660000001)
Asn Gln Trp Trp
C31H36N8O7 (632.2706826000001)
Asn Trp Lys Trp
C32H40N8O6 (632.3070660000001)
Asn Trp Gln Trp
C31H36N8O7 (632.2706826000001)
Asn Trp Trp Lys
C32H40N8O6 (632.3070660000001)
Asn Trp Trp Gln
C31H36N8O7 (632.2706826000001)
Gln His Trp Tyr
C31H36N8O7 (632.2706826000001)
Gln His Tyr Trp
C31H36N8O7 (632.2706826000001)
Gln Asn Trp Trp
C31H36N8O7 (632.2706826000001)
Gln Trp His Tyr
C31H36N8O7 (632.2706826000001)
Gln Trp Asn Trp
C31H36N8O7 (632.2706826000001)
Gln Trp Trp Asn
C31H36N8O7 (632.2706826000001)
Gln Trp Tyr His
C31H36N8O7 (632.2706826000001)
Gln Tyr His Trp
C31H36N8O7 (632.2706826000001)
Gln Tyr Trp His
C31H36N8O7 (632.2706826000001)
Trp Glu Ile Trp
C33H40N6O7 (632.2958330000001)
Trp Glu Leu Trp
C33H40N6O7 (632.2958330000001)
Trp Glu Trp Ile
C33H40N6O7 (632.2958330000001)
Trp Glu Trp Leu
C33H40N6O7 (632.2958330000001)
Trp His Lys Tyr
C32H40N8O6 (632.3070660000001)
Trp His Gln Tyr
C31H36N8O7 (632.2706826000001)
Trp His Tyr Lys
C32H40N8O6 (632.3070660000001)
Trp His Tyr Gln
C31H36N8O7 (632.2706826000001)
Trp Ile Glu Trp
C33H40N6O7 (632.2958330000001)
Trp Ile Trp Glu
C33H40N6O7 (632.2958330000001)
Trp Lys His Tyr
C32H40N8O6 (632.3070660000001)
Trp Lys Asn Trp
C32H40N8O6 (632.3070660000001)
Trp Lys Trp Asn
C32H40N8O6 (632.3070660000001)
Trp Lys Tyr His
C32H40N8O6 (632.3070660000001)
Trp Leu Glu Trp
C33H40N6O7 (632.2958330000001)
Trp Leu Trp Glu
C33H40N6O7 (632.2958330000001)
Trp Asn Lys Trp
C32H40N8O6 (632.3070660000001)
Trp Asn Gln Trp
C31H36N8O7 (632.2706826000001)
Trp Asn Trp Lys
C32H40N8O6 (632.3070660000001)
Trp Asn Trp Gln
C31H36N8O7 (632.2706826000001)
Trp Gln His Tyr
C31H36N8O7 (632.2706826000001)
Trp Gln Asn Trp
C31H36N8O7 (632.2706826000001)
Trp Gln Trp Asn
C31H36N8O7 (632.2706826000001)
Trp Gln Tyr His
C31H36N8O7 (632.2706826000001)
Trp Trp Glu Ile
C33H40N6O7 (632.2958330000001)
Trp Trp Glu Leu
C33H40N6O7 (632.2958330000001)
Trp Trp Ile Glu
C33H40N6O7 (632.2958330000001)
Trp Trp Lys Asn
C32H40N8O6 (632.3070660000001)
Trp Trp Leu Glu
C33H40N6O7 (632.2958330000001)
Trp Trp Asn Lys
C32H40N8O6 (632.3070660000001)
Trp Trp Asn Gln
C31H36N8O7 (632.2706826000001)
Trp Trp Gln Asn
C31H36N8O7 (632.2706826000001)
Trp Tyr His Lys
C32H40N8O6 (632.3070660000001)
Trp Tyr His Gln
C31H36N8O7 (632.2706826000001)
Trp Tyr Lys His
C32H40N8O6 (632.3070660000001)
Trp Tyr Gln His
C31H36N8O7 (632.2706826000001)
Tyr His Lys Trp
C32H40N8O6 (632.3070660000001)
Tyr His Gln Trp
C31H36N8O7 (632.2706826000001)
Tyr His Trp Lys
C32H40N8O6 (632.3070660000001)
Tyr His Trp Gln
C31H36N8O7 (632.2706826000001)
Tyr Lys His Trp
C32H40N8O6 (632.3070660000001)
Tyr Lys Trp His
C32H40N8O6 (632.3070660000001)
Tyr Gln His Trp
C31H36N8O7 (632.2706826000001)
Tyr Gln Trp His
C31H36N8O7 (632.2706826000001)
Tyr Trp His Lys
C32H40N8O6 (632.3070660000001)
Tyr Trp His Gln
C31H36N8O7 (632.2706826000001)
Tyr Trp Lys His
C32H40N8O6 (632.3070660000001)
Tyr Trp Gln His
C31H36N8O7 (632.2706826000001)
Coagulin R 3-glucoside
3,9-bis(2,6-di-tert-butyl-4-methylphenoxy)-2,4,8,10-tetraoxa-3,9-diphosphaspiro[ 5.5]undecane (PEP-36)
(7a,17b)-7-[9-[(4,4,5,5,5-Pentafluoropentyl)thio]nonyl]-estra-1,3,5(10)-triene-3,17-diol 17-acetate
[D-Ala2,4,Tyr5] -b-Casomorphin (1-5)
C33H40N6O7 (632.2958330000001)
Phenyl2,3,4,6-tetra-O-benzyl-b-D-thiogalactopyranoside
Bis[4-(9,9-diMethyl-9,10-dihydroacridine)phenyl]solfone
Sitoindoside IX
A withanolide saponin that consists of withaferin A attached to a beta-D-glucopyranosyl residue at position 27 via a glycosidic linkage. Isolated from Physalis longifolia, it exhibits antineoplastic activity.
1-{3-Methyl-2-[4-(morpholine-4-carbonyl)-benzoylamino]-butyryl}-pyrrolidine-2-carboxylic acid (3,3,4,4,4-pentafluoro-1-isopropyl-2-oxo-butyl)-amide
Losalen
D000893 - Anti-Inflammatory Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D012459 - Salicylates
(31R)-8,12-diethyl-71,71-dihydroxybacteriochlorophyllide c
O-methyl-4-O-[2,4-di-O-methyl-alpha-L-fucopyranosyl-(1->3)-alpha-L-rhamnopyranosyl-(1->3)-2-O-methyl-alpha-L-rhamnopyranosyl]-hydroxybenzoate
2-[[(2R)-3-acetyloxy-2-[(5R,6R,7Z,9Z,11E,13E,15S,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-2-acetyloxy-3-[(5S,6S,7Z,9Z,11E,13E,15R,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
1-[[(2R,3R)-10-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
C30H35F3N6O6 (632.2570046000001)
[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
3-(1-hydroxyethyl)chlorophyllide a
A chlorophyllide obtained by hydrolysis of the terpenoid ester moiety of 3-(1-hydroxyethyl)chlorophyll a.
3-(1-hydroxyethyl)bacteriochlorophyllide a(2-)
A cyclic tetrapyrrole anion that is obtained from 3-(1-hydroxyethyl)bacteriochlorophyllide a via deprotonation of the carboxy group and formation of a carbide ion. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).
14-(acetyloxy)-6-(furan-3-yl)-15,16-dihydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadecan-18-yl 2-methylpropanoate
(1s,3r,5r,6as,7s,8s,9r,10r,10as)-1,3-bis(acetyloxy)-7-[(2r)-2-hydroperoxy-3-methylidenepent-4-en-1-yl]-5,9-dihydroxy-7,8-dimethyl-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-10-yl (2z,4e)-deca-2,4-dienoate
8-(acetyloxy)-8a-[(acetyloxy)methyl]-5,6-dimethyl-5-{2-[(2-methylbutanoyl)oxy]-2-(5-oxo-2h-furan-3-yl)ethyl}-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-4-yl 2-methylbut-2-enoate
(6r,14r)-13-hydroxy-6,14-diisopropyl-2,2,4,4,8,8,10,10-octamethyl-12-(2-methylpropanoyl)-6,14-dihydro-5,11-dioxapentaphene-1,3,7,9-tetrone
(1r,4ar,5s,6s,8s,8ar)-5-[(1s)-1-(acetyloxy)-2-(5-oxo-2h-furan-3-yl)ethyl]-8-(benzoyloxy)-6-hydroxy-5,6-dimethyl-hexahydrospiro[naphthalene-1,2'-oxiran]-8a-ylmethyl benzoate
(1s,2r,4s,5r,6s,7s,8r,9r,12r)-4,5,8,12-tetrakis(acetyloxy)-6-[(acetyloxy)methyl]-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate
(1s,2r,4r,5r,6s,8r,10s,11s,12r,14r,15s,19r,20r,21s)-20-(acetyloxy)-6-(furan-3-yl)-4,12,19,21-tetrahydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-16-yl 2-methylbutanoate
methyl (2r,4ar,6r,6as,10ar,10bs)-2-[(2s,3s,4s,5s)-3,4-dihydroxy-2,5-dimethoxyoxolan-3-yl]-6a,10b-dimethyl-4-oxo-6-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,4ah,5h,6h,9h,10h,10ah-naphtho[2,1-c]pyran-7-carboxylate
6-[(acetyloxy)methyl]-7-(furan-3-carbonyloxy)-2,12-dihydroxy-2,10,10-trimethyl-5-[(2-methylbutanoyl)oxy]-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-4-yl furan-3-carboxylate
(3s,4r,4ar,6s,7r,7ar)-3-hydroxy-4-(methoxycarbonyl)-7-methyl-octahydrocyclopenta[c]pyran-6-yl (4s,5s,6s)-4-(2,2-dimethoxyethyl)-5-ethenyl-6-{[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylate
methyl 2-(3,4-dihydroxy-2,5-dimethoxyoxolan-3-yl)-6a,10b-dimethyl-4-oxo-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,4ah,5h,6h,9h,10h,10ah-naphtho[2,1-c]pyran-7-carboxylate
5-{[8a-(5,7-dihydroxy-4-oxochromen-2-yl)-6-methoxy-2-methyl-5,8-dioxo-4,4a-dihydro-1h-naphthalen-1-yl]methyl}-7-hydroxy-1,4a-dimethyl-6-methylidene-hexahydro-2h-naphthalene-1-carboxylic acid
4,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-2-hydroxy-2,10,10-trimethyl-5-[(2-methylbutanoyl)oxy]-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate
(1s,3s,4s,5r,6r,7r)-1-[(3e)-3,5-dimethyl-6-phenylhex-3-en-1-yl]-6-{[(2e,4s,6s)-4,6-dimethyloct-2-enoyl]oxy}-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
12-deacetyltrichilin i
{"Ingredient_id": "HBIN000775","Ingredient_name": "12-deacetyltrichilin i","Alias": "NA","Ingredient_formula": "C33H44O12","Ingredient_Smile": "NA","Ingredient_weight": "632.703","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "9367","PubChem_id": "NA","DrugBank_id": "NA"}
15-acetoxy-2α,9β-di-(β-furancarbonyloxy)-4β,6β-dihydroxy-1α-(2-methylbutanoyloxy)-dihydro-β-agarofuran
{"Ingredient_id": "HBIN001601","Ingredient_name": "15-acetoxy-2\u03b1,9\u03b2-di-(\u03b2-furancarbonyloxy)-4\u03b2,6\u03b2-dihydroxy-1\u03b1-(2-methylbutanoyloxy)-dihydro-\u03b2-agarofuran","Alias": "NA","Ingredient_formula": "C32H40O13","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "160","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
1-deoxy-11-methoxy-3- tigloyloxymeliacarpinin
{"Ingredient_id": "HBIN002474","Ingredient_name": "1-deoxy-11-methoxy-3- tigloyloxymeliacarpinin","Alias": "NA","Ingredient_formula": "C33H44O12","Ingredient_Smile": "NA","Ingredient_weight": "632.703","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "9220","PubChem_id": "NA","DrugBank_id": "NA"}
6α-acetoxy-9β-benzoyloxy-1β-cinnamoyloxy-8β-butanoyloxy-β-dihydroagarofuran
{"Ingredient_id": "HBIN012195","Ingredient_name": "6\u03b1-acetoxy-9\u03b2-benzoyloxy-1\u03b2-cinnamoyloxy-8\u03b2-butanoyloxy-\u03b2-dihydroagarofuran","Alias": "NA","Ingredient_formula": "C37H44O9","Ingredient_Smile": "CCCC(=O)OC1C2C(C3(C(CCC(C3(C1OC(=O)C4=CC=CC=C4)C)OC(=O)C=CC5=CC=CC=C5)C)OC2(C)C)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "131","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
6″-O-trans-sinapoylgenipin gentiobioside
{"Ingredient_id": "HBIN012724","Ingredient_name": "6\u2033-O-trans-sinapoylgenipin gentiobioside","Alias": "NA","Ingredient_formula": "C34H48O11","Ingredient_Smile": "CC1C(C(C(OC1COC2C(C(C(C(O2)CO)O)O)O)OC(=O)C(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=O)C)C)O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "40184","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}